Your browser doesn't support javascript.
loading
[Drug regulatory authorities in South America: an analysis based on organizational rules]. / Autoridades reguladoras de medicamentos sul-americanas: uma análise a partir de regras organizacionais.
Sandri, Mariane Martins da Silva; De Seta, Marismary Horsth; Luiza, Vera Lucia.
Afiliação
  • Sandri MM; Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
Rev Panam Salud Publica ; 34(3): 169-75, 2013 Sep.
Article em Pt | MEDLINE | ID: mdl-24233109
OBJECTIVE: To describe the organization of national drug regulatory authorities (DRAs) in Argentina, Brazil, Chile, and Peru through the analysis of categories representing organizational rules. METHODS: The DRAs were selected using the following criteria: being in a South American country, having been identified as DRAs at Encuentros de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (Conferences of Ibero-American Drug Regulatory Authorities), and having good availability of electronic data regarding organizational structure and the process of drug regulation. The main source of data were websites, which were reviewed between May 2010 and March 2011. The analytical categories were: organizational structure, competencies, directionality (mission and vision statements), and forms of accountability. RESULTS: The DRAs of Argentina and Brazil functioned as autonomous agencies, while those of Chile and Peru were directly subordinated to the ministries of health. Except for the Brazilian DRA, the agencies in the other three countries were dependent on their health ministries to issue sanitary regulations. The scope of action of each DRA differed in terms of the goods and services covered, with the Peruvian DRA being the only one exclusively dedicated to the regulation of drugs. The four DRAs performed all the processes identified by the World Health Organization as essential for effective drug regulation. CONCLUSIONS: The results show an effort by the studied countries to improve their regulatory structure. Nevertheless, all four DRAs need to improve some mechanisms to ensure that, at the end of the regulatory chain, the drugs they regulate have the desired quality and safety, with more transparency in decision-making processes and social accountability.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Controle de Medicamentos e Entorpecentes Tipo de estudo: Prognostic_studies País/Região como assunto: America do sul Idioma: Pt Revista: Rev Panam Salud Publica Assunto da revista: SAUDE PUBLICA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Controle de Medicamentos e Entorpecentes Tipo de estudo: Prognostic_studies País/Região como assunto: America do sul Idioma: Pt Revista: Rev Panam Salud Publica Assunto da revista: SAUDE PUBLICA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos